Research and Markets: EpiCast Report: Amyotrophic Lateral Sclerosis - Epidemiology Forecast to 2023

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/x75nfr/epicast_report) has announced the addition of the "EpiCast Report: Amyotrophic Lateral Sclerosis - Epidemiology Forecast to 2023" report to their offering.

The diagnosed prevalent cases of ALS in the 7MM will increase from 32,698 cases in 2013 to 37,122 cases in 2023, at a growth rate of 13.5% over the forecast period. Throughout the forecast period, the US will have the highest numbers of diagnosed prevalent cases of ALS, followed by Japan, where the two markets combined will constitute more than 50% of the diagnosed prevalent cases in the 7MM. The authors epidemiologists attribute the growth in the diagnosed prevalent cases of ALS in the 7MM to the changing population demographics in the respective markets.

This report provides an overview of the risk factors, comorbidities, and the global and historical trends for ALS in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). In addition, the report includes a 10-year epidemiological forecast (2013-2023) for the diagnosed prevalent cases of ALS segmented by sex and age (in 10-year age groups, beginning at age 40 years and ending at age =80 years). To forecast the diagnosed prevalent cases of ALS in the 7MM, The authors epidemiologists used only country-specific studies that provided the diagnosed prevalence of ALS using uniform diagnostic criteria based on the El Escorial criteria or the International Classification of Diseases, Ninth Revision (ICD-9), criteria (ICD-9 code for ALS = 335.2), to allow for a meaningful comparison of the diagnosed prevalent cases of ALS in these markets.

Key Topics Covered:

1 Tables & Figures

2 Introduction

2.1 Catalyst

2.2 Upcoming Reports

3 Epidemiology

3.1 Disease Background

3.2 Risk Factors and Comorbidities

3.3 Global Trends

3.4 Forecast Methodology

3.4.1 Sources Used

3.4.2 Sources Not Used

3.4.3 Forecast Assumptions and Methods

3.5 Epidemiological Forecast for Amyotrophic Lateral Sclerosis (2013-2023)

3.5.1 Diagnosed Prevalent Cases of ALS

3.5.2 Age-Specific Diagnosed Prevalent Cases of ALS

3.5.3 Sex-Specific Diagnosed Prevalent Cases of ALS

3.5.4 Age-Standardized Diagnosed Prevalence of ALS

3.6 Discussion

3.6.1 Epidemiological Forecast Insight

3.6.2 Limitations of the Analysis

3.6.3 Strengths of the Analysis

4 Appendix

For more information visit http://www.researchandmarkets.com/research/x75nfr/epicast_report

Contacts

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Central Nervous System

Contacts

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Central Nervous System